Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports KDS2010 a Novel Oral Tablet Phase 2 Trial for Alzheimer's Disease (AD) Currently Enrolling with U.S. Patient Cohort to be Added in 2025

Core Insights - KDS2010 (Tisolagiline) is a new reversible selective monoamine oxidase B (MAO-B) inhibitor being studied for its potential in treating neurodegenerative diseases like Alzheimer's disease, with a Phase 2 clinical trial currently enrolling patients in South Korea and a U.S. cohort expected to be added in 2025 [1][5] - The global Alzheimer's drug market is projected to exceed $15 billion by 2030, driven by the introduction of new drugs that aim to slow cognitive decline [1] Company Overview - Scilex Bio, a joint venture between Scilex Holding Company and IPMC Company, holds the exclusive rights to KDS2010's global license and is focused on developing this novel treatment for Alzheimer's disease [1][15] - Scilex Holding Company is headquartered in Palo Alto, California, and is dedicated to acquiring, developing, and commercializing treatments for neurodegenerative diseases and non-opioid pain management products [11][20] Clinical Development - KDS2010 has shown favorable safety and tolerability in Phase 1 clinical trials involving 88 healthy young adults and elderly subjects, demonstrating adequate pharmacokinetics for once-daily dosing [1][5] - The ongoing Phase 2 clinical trial aims to evaluate the safety and efficacy of KDS2010 in patients with mild cognitive impairment and mild dementia [1][5] Mechanism of Action - KDS2010 not only acts as a MAO-B inhibitor but also influences astrocytic GABA inhibition, which is crucial in regulating neurotransmitter systems and addressing cognitive decline and neuroinflammation in Alzheimer's disease [1][3] - By inhibiting astrocytic GABA signaling, KDS2010 aims to reduce neuroinflammation and restore the balance between excitatory and inhibitory signals in the brain, potentially enhancing cognitive function [3][4] Market Potential - The advancement of small molecules like KDS2010, which can be administered orally once daily, represents a promising alternative to current injectable treatments targeting amyloid, tau, or neuroinflammation in Alzheimer's disease [2]